# A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Study · id `cardio:ct-nct06933472` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06933472](<https://clinicaltrials.gov/study/NCT06933472>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06933472

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.

## Technical summary

Registry record NCT06933472. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-13 (actual); primary completion 2026-06-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 264 participants (planned count; ClinicalTrials.gov record NCT06933472, source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)
- Started: 2025-06-13 (actual) (ClinicalTrials.gov record NCT06933472, source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)
- Primary completion: 2026-06-20 (anticipated) (ClinicalTrials.gov record NCT06933472, source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)
- Completion: 2027-01-10 (anticipated) (ClinicalTrials.gov record NCT06933472, source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)
- Countries: United States; China (ClinicalTrials.gov record NCT06933472, source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06933472-2026-01-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
- Acronym: RESPOND-2
- Condition: Hyperphosphatemia
- Condition: Chronic Kidney Disease, Receiving Dialysis
- Condition: ESRD (End-Stage Renal Disease)
- Condition: Dialysis
- Intervention (Drug): AP301
- Intervention (Drug): AP301 Low Dose
- Lead sponsor: Alebund Pharmaceuticals
- Lead sponsor class: INDUSTRY
- Collaborator: Fortrea
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as a collaborator: Fortrea (`cardio:org-fortrea`)

## Provenance

Content hash: 3c03c48b9487d2f00bd4ce124aea53a6f6b997bf2edff0ca39cb189dc63a5012
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
